Inventiva S.A.

Inventiva S.A. is a clinical-stage biopharmaceutical company that develops oral small molecule therapies. The company was founded in 2011 and incorporated in France in 2016 as a *société anonyme*, or S.A., for a period of 99 years. Its principal executive offices are located at 50 rue de Dijon, 21121 Daix, France. Inventiva S.A. is registered at the Dijon Trade and Companies Register (*Registre du commerce et des sociétés*) under the number 537 530 255. The company focuses on developing treatments for MASH (Metabolic Dysfunction-Associated Steatohepatitis). Inventiva S.A. operates a wholly-owned research and development facility and has a team experienced in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. The company is currently advancing lanifibranor for the treatment of MASH and also has a pipeline of earlier stage therapeutic programs in oncology. Inventiva S.A. completed an initial public offering of its ordinary shares on Euronext Paris in February 2017 and an initial public offering of its ordinary shares in the form of American Depositary Shares, or ADSs, on the Nasdaq Global Market in July 2020. Capital expenditures for the years ended December 31, 2025, 2024, and 2023 amounted to 247,483, 422,385, and 539,827, respectively. These expenditures primarily covered the acquisition of research equipment and technical installations in France.